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Background and Aim. Interleukin-21 (IL-21) is primarily a T cell-derived cytokine; it is upregulated in patients with Crohn’s
Disease (CD) and could be a potential new therapeutic target in CD. Methods. In human material, IL-21 and IL-21R
expression was investigated by in situ hybridization (ISH) and immunohistochemistry (IHC) in noninﬂammatory bowel disease
(non-IBD) controls and patients with CD. The pathologic role of IL-21 was examined in murine models of T cell-dependent
and T cell-independent colitis, either with a neutralizing monoclonal antibody against IL-21 or with the transfer of
CD4+CD45RBhighIL-21R−/− T cells. Colonic pathology was examined by endoscopy, histopathology, IHC, ELISA, and Luminex.
Results. In the human intestine, IL-21 and IL-21R mRNA and protein-expressing cells were observed in the mucosa, in
lymphoid aggregates of submucosa in non-IBD controls, and in lymphoid aggregates of muscularis externa in patients with
CD. IL-21 expression was most abundant in germinal centers (GCs) of the lymphoid aggregates, and IL-21R expression
assessed semiquantitatively, was signiﬁcantly higher in patients with CD compared to non-IBD controls. Following
prophylactic and interventive anti-IL-21 mAb treatment in the adoptive transfer (AdTr) model, clinical and pathological
parameters were signiﬁcantly reduced. The most persistent ﬁnding was a reduction in colonic inﬁltrating neutrophils. As well,
Rag2−/− mice receiving CD4+CD45RBhighIL-21R−/− T cells developed less severe colitis compared to Rag2−/− mice receiving
CD4+CD45RBhighIL-21R+/+ T cells. No eﬀect of reduced IL-21 signalling was observed in T cell-independent colitis. Conclusion.
Our study shows that patients with CD have signiﬁcant expression of IL-21 and IL-21R in the gut. As well, we show that
neutralization of IL-21 in experimental T cell-driven colitis is associated with a reduction in clinical and pathological ﬁndings.
This amelioration seems to be associated with a reduction in colon-inﬁltrating neutrophils.
1. Introduction
Inﬂammatory bowel disease (IBD) is a refractory chronic
inﬂammatory disease in the intestine. The disease is divided
into ulcerative colitis (UC) and Crohn’s disease (CD). IBD is
deﬁned by clinical symptoms and radiological, endoscopic,
and histopathological ﬁndings [1, 2]. Although its pathogen-
esis is still unclear, many studies have suggested it is a mul-
tifactorial disease involving genetic and environmental
factors that cause an abnormal immune response to the
gut microﬂora [3]. Diﬀerences in the histopathology of CD
and UC clearly exist. Where UC is characterized by diﬀuse
inﬂammation conﬁned to the mucosa of the colon and rec-
tum [2], the inﬂammation of CD is discontinuous and
transmural and can aﬀect the entire gastrointestinal tract
[1]. Patients with CD often present complications like intes-
tinal strictures, ﬁstulas, and abscesses which make disease
management challenging [1]. Within the last 15 years,
tumour necrosis factor α (TNFα) antagonists have trans-
formed the medical treatment of moderate to severe CD,
even though a signiﬁcant proportion of patients with CD
do not respond adequately to treatment with these agents.
Primary and secondary nonresponders to anti-TNFα ther-
apy present a clinical challenge and require dose adjustment
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or switch to another medication. The eﬃcacy of the treat-
ment of anti-TNFα-resistant CD appears to be quite modest
[4]. Thus, new drug candidates are clearly needed for the
anti-TNFα nonresponders.
Disruption of the CD4+ T cell balance is an important
part of CD pathogenesis [5, 6], and cytokines are principal
mediators orchestrating this disturbance [5]. Thus, various
cytokines have been targeted or suggested as targets for the
treatment of CD [7].
IL-21 is predominantly expressed by activated Th17 cells
[8, 9], T follicular helper cells [10] and NKT cells [11, 12]. IL-
21 signals through a receptor composed of a speciﬁc subunit,
termed IL-21R, and the common γ-chain subunit, shared
with IL-2, IL-4, IL-7, IL-9, and IL-15 receptors [13, 14]. IL-
21R is highly expressed on T and B lymphocytes [15, 16],
natural killer (NK) cells, and some nonhematopoietic cells,
all of which functionally respond to IL-21 [13, 17]. Previous
studies have shown that IL-21 is important in the regulation
of immunoglobulin synthesis by plasma cells [18], cytotoxic
activity of NK cells, and CD8+ T cells [17]. As well, IL-21
has been reported to be a key modulator of TGF-β signalling,
leading to reciprocal diﬀerentiation of Treg and Th17 cells
[19, 20]. During T cell diﬀerentiation, IL-21 is believed to
sustain IL-23R expression, which then allows increased cellu-
lar response to IL-23 [11]. IL-21 may also act through the
induction of the transcription factor retinoic acid receptor-
related orphan receptor (RORγt) [8, 21]. In IBD patients,
IL-21 has been reported to be expressed by IFN-γ-producing
CD4+ T cells [22], as well as Th17 cells [6, 23]. In the gut,
Th17 cells can have tissue-protective eﬀects and enhance epi-
thelial barrier function, as well as increasing the synthesis of
extracellular matrix-degrading proteases, inﬂammatory cyto-
kines, chemokines, and adhesion molecules and recruitment
of neutrophils [21, 24]. In patients with CD, some of the IL-
17A-producing cells coexpress IFN-γ and/or FoxP3 and may
undergo transformation into typical Th1 or Treg cells depen-
dent on the costimulatory environment [25, 26].
In IBD, it is currently unknown whether IL-21 directly
aﬀects Treg proliferation, diﬀerentiation, and suppression
or reduces the frequency of FoxP3-positive cells by promot-
ing Th17 cells.
Enhanced expression of IL-21 and/or IL-21R has been
documented in various diseases including CD, UC, and celiac
disease [11, 22, 24, 27, 28]. The upregulation of T cell-
secreted IL-21 has in particular been described in patients
with CD and celiac disease [22, 27]. Traditionally, CD can
be categorized into ileum, ileocolonic, and colon subtypes,
based on disease location [1]. Still, these subtypes behave
similarly in terms of IL-21 upregulation [29], indicating that
upregulation of IL-21 may be a general mechanism in CD.
Moreover, there is evidence that the blockade of IL-21 signal-
ling by either gene-targeting studies or IL-21R-Fc treatment
limits the severity of inﬂammation in experimental models
of immune-mediated diseases [11, 30–34]. In these studies,
IL-21 has been described to work through a modulation of
immune cell traﬃcking and downregulation of ﬁbroblast-
secreted matrix-degrading enzymes in the gut [35, 36].
Mutations in IL-21 or IL-21R seem to work diﬀerently in
humans, where severe immune dysregulation characterized
by infectious susceptibility to opportunistic pathogens and,
paradoxically, autoimmunity has been reported in a few
cases [37–39]. The pleiotropic eﬀect of IL-21 is also reﬂected
in a range of clinical trials where IL-21 showed immune
stimulatory eﬀects, acceptable toxicity, and antitumour
eﬀects in a fraction of cancer patients [40]. Anti-IL-21
mAb treatment has been evaluated in rheumatoid arthritis,
systemic lupus erythematosus, and CD [11]. More recently,
the role of anti-TNFα mAb in regulating IL-21 expression
and Th17 cell inﬁltration in the intestinal mucosa of CD
patients was explored [41]. IL-21 and Th17 cells were found
to be highly expressed in the inﬂamed mucosa of active CD
patients compared with healthy controls. Ten weeks after
anti-TNFα mAb infusion, intestinal mucosal healing was
improved in CD patients and IL-21 expression and Th17
cell inﬁltration were found to be signiﬁcantly decreased
[41]. Similarly, IL-21 transcripts in the intestinal tissue from
CD patients have been reported to be signiﬁcantly downreg-
ulated in anti-TNFα responders, but not in nonresponders
[42]. Thus, IL-21 seems to follow CD pathogenesis and
could be a potential target in both anti-TNFα mAb
responders and nonresponders.
We demonstrate that in human intestinal material IL-21
and IL-21R expression follows the hallmark of CD, the trans-
mural inﬂammation, and that IL-21R is expressed by subsets
of T cells, B cells, and plasma cells located in particular ger-
minal centers (GCs) of lymphoid aggregates and in those
inﬁltrating the intestinal wall in general.
We also demonstrate that IL-21 neutralization only is
eﬃcacious in models with CD4 T cell-driven colitis and pri-
marily aﬀects homing of calprotectin-positive cells.
2. Materials and Methods
2.1. Bioethics. All human materials were obtained with
informed consent from the donors/or close relatives and
approval from relevant local ethical committees (H-KF-2007-
0048, Rigshospitalet, Copenhagen, Denmark; Cambridge
Biosciences, Supplier information: Tissue Supply Network
(http://www.bioscience.co.uk)).
All mouse experiments were carried out in accordance
with the European Communities Council Directive 2010/
63/EU for the protection of animals used for experimental
purposes and approved by the Danish Animal Experiments
Inspectorate, Ministry of Food, Agriculture and Fisheries,
Denmark, as well as the Internal Ethical Review Committee
at Novo Nordisk A/S. Mice were sacriﬁced by cervical dislo-
cation if their weight loss exceeded 20% within the study or if
they had a morbid appearance.
2.2. Human Material. Human tissue samples used for either
in situ hybridization (ISH) or immunohistochemical (IHC)
investigations of IL-21 and IL-21R mRNA or protein expres-
sion are listed in Table 1.
2.3. Sectioning. Frozen cell and tissue sections were cut at a
nominal thickness of 5μm mounted on Superfrost® Plus
microscope slides, air dried, and stored at −80°C until further
processing. Fixed paraﬃn-embedded cell and tissue sections
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were cut at a nominal thickness of 3μm, mounted on
Superfrost Plus microscope slides, and stored at −20°C until
further processing.
2.4. Probes. Human IL-21 (ENSG00000138684) and IL-
21R (AC HS02517) cDNA fragments (344–833 bp and
725–1183 bp, resp.) were labelled with 35S as previously
described [43, 44].
2.5. Antibodies for Human Study. Antibodies and conjugated
detection kits used for immunohistochemical studies are
listed in Supplementary Table 1. Approximately, 100
diﬀerent anti-human IL-21 antibodies (commercially
available and in-house produced) were evaluated on human
IL-21 or mock transfected cells and positive control tissue
(tonsil). One was found to be speciﬁc for recombinant
human IL-21 NNC0114-0000-0032.
2.6. In Situ Hybridization on Human Tissue. ISH was per-
formed on frozen sections as previously described with
minor modiﬁcations [43, 44]. The protocol is described in S1.
2.7. Immunohistochemistry on Human Tissue. The sections
were deparaﬃnised in xylene and rehydrated in decreasing
concentrations of alcohols. Antigen retrieval was performed
in Tris-EGTA buﬀer (10mM; 0.5mM), pH9.0 in a micro-
wave oven for 15min. Endogenous peroxidase activity was
blocked with 3%H2O2 and dual block (Dako, S2003). Endog-
enous biotin was blocked by incubation with avidin and
biotin blocking solutions for 10min, according to the manu-
facturer. Nonspeciﬁc binding was blocked by incubation with
TBS containing 3% skimmed milk, 7% donkey serum, 3%
human serum, and 3.2mg/ml poly-L-lysine (PLL) for
30min. The primary and secondary antibodies were diluted
in a Tris buﬀer containing 0.5% skimmed milk, 7% donkey
serum, 3% human serum, and 3.2mg/ml PLL, and incubation
was performed overnight at 4°C and 60min at room temper-
ature, respectively. The ﬁrst ampliﬁcation step was performed
by incubation with Vectastain ABC peroxidase kit, diluted in
0.1M Tris-HCl buﬀer (pH7.5) containing 0.5% Du Pont
blocking reagent (TNB) for 30min, followed by a second
ampliﬁcation step with incubation in biotinylated tyramide
for 6min. The ﬁnal ampliﬁcation was performed by an addi-
tional incubation with the Vectastain ABC peroxidase kit,
diluted as previously described for 30min. The chromogenic
reaction was achieved with diaminobenzidine. Nuclei were
counterstained with haematoxylin, and the sections were
rehydrated, cleared in xylene, and mounted with Pertex.
The evaluation of the slides was performed by the blinded
observer. The sections were evaluated by virtual microscopy
using a Hamamatsu NanoZoomer (Hamamatsu Denmark,
Ballerup, Denmark) and conventional microscopy using an
Olympus BX51 microscope equipped with a DP70 digital
camera (Olympus Denmark A/S, Ballerup, Denmark).
2.8. Double Immunoﬂuorescence on Human Tissue. The
immunohistochemical demonstration of the IL-21R was in
general performed as described above. Upon the second
ampliﬁcation with biotinylated tyramide for 3min, sections
were incubated with the Vectastain ABC peroxidase kit,
diluted as previously described for 30min. The ﬁnal ampliﬁca-
tion was performed by incubation with Alexa-594 conjugated
tyramide diluted according to the manufacturer for 6min. The
sections were then subjected to second rounds of microwave
oven treatment in Tris-EGTA buﬀer (10mM; 0.5mM),
pH9.0 for 10min, blocking of endogenous peroxidase activity
with 3% H2O2, and endogenous biotin by incubation with
avidin and biotin blocking solutions for 10min, respectively,
according to the manufacturer. Additional blocking of
nonspeciﬁc binding was performed by incubation with TBS
containing 3% skimmed milk, 7% donkey serum, and 3%
human serum for 30min. The second primary and secondary
antibodies were diluted in a Tris buﬀer containing 0.5%
skimmed milk, 7% donkey serum, and 3% human serum,
and incubation was performed overnight at 4°C and 60min
at room temperature, respectively. The ﬁnal ampliﬁcations
were performed by an additional incubation with the Vectas-
tain ABC peroxidase kit, diluted as previously described for
30min, and incubation with Alexa-488 conjugated tyramide.
The nuclei were counterstained with Hoechst for 15min,
and the sections were ﬁnally mounted in ﬂuorescence mount-
ing media (Dako). The sections were evaluated by virtual
microscopy using a Hamamatsu NanoZoomer (Hamamatsu
Table 1: Human tissues used in the present study.
Tissue
Processed
Vendor
FF∗ (ISH) FFPE∗ (IHC) PFPE∗ (IHC)
Positive control tissue
Tonsil 3 5 Rigshospitalet (Copenhagen, DK)
Normal non-IBD controls∗∗
Colon 14 15 Cambridge BioScience (Cambridge, UK)
Small intestine 3 3 Cambridge BioScience (Cambridge, UK)
Crohn’s disease
Colon 8 10 Cambridge BioScience (Cambridge, UK)
Small intestine 7 10 Cambridge BioScience (Cambridge, UK)
FF: fresh frozen OCT embedded; FFPE: formalin-ﬁxed paraﬃn embedded; IHC: immunohistochemistry; IBD: inﬂammatory bowel disease; ISH: in situ
hybridization; PFPE: paraformaldehyde-ﬁxed paraﬃn embedded. ∗Number of samples is listed. ∗∗Pathologically classiﬁed as being within normal limits
obtained from patients with adenocarcinoma, gastrointestinal tumour of small intestine, lipoma, dysplasia of bile duct epithelium, and familial adenomatous
polyposis.
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Denmark, Ballerup, Denmark) and an FV10i Laser scanning
microscope (Olympus Denmark A/S, Ballerup, Denmark).
2.9. Semiquantitative Scoring on Human Tissue. IL-21R
immunopositive (IL-21R+) cells were semiquantitatively
scored as follows: Themucosa-associated lymphoid compart-
ments were individually scored: mucosa (M): intraepithelial
lymphocyte (IEL) compartment (surface epithelium), lamina
propria, and follicle-associated epithelium (FAE); submucosa
(SM): isolated (solitary) lymphoid follicles (ILF), Peyer’s
patches (ileum)/colonic IEL (colon), and isolated inﬁltrating
lymphocytes; and muscularis externa (ME): IELs and isolated
inﬁltrating lymphocytes. Each compartment was scored on a
scale from 0 to 4: 0, no; 1, few; 2 moderate; 3, many; and 4,
abundant numbers of IL-21R+ cells. An accumulated score
was calculated for each intestinal layer (M, SM, and ME)
and in total (M+SM+ME) for the entire intestine: max
score—M=12, SM=12, andME=8 and entire intestine = 32.
2.10. Mice and Housing. B6.129P2-Il10138 tm1Cgn/J (IL-
10−/−)mice andC57BL/6Jwild-type (WT)micewere obtained
from Charles River Laboratories (Sulzfeld, Germany) in
accordance with a licence agreement with MCG (Munich,
Germany). C.B-17 severe combined immunodeﬁciency
(SCID) mice, BALB/c, NMRI, C57BL/6NTac, B6.129.
S6Rag2tm1FwaN12 mice, IL-21R−/−C57BL/6, and IL-
21R+/+C57BL/6 littermates were purchased from Taconic
M&B (Ry, Denmark). Female mice, 8–12 weeks old, were
used in all the studies. The mice were housed at Novo
Nordisk A/S, Maaloev, Denmark, and kept under barrier-
protected conditions free of agents listed in FELASA guide-
lines [45] as follows: 10–12 mice per cage and a 12-hour
light/dark cycle. 90 percent of the cage bedding was changed
weekly, and 10 percent of the cage bedding was transferred
between cages in order to ensure a homogenous microbial
environment. The clinical status of the mice was evaluated
three times weekly by visual inspection, percentage weight
change, and faecal consistency.
2.11. Induction of Adoptive Transfer Colitis Using CD4+
CD25− T Cells. The transfer colitis with CD4+CD25− T cells
was conducted as previously described [46, 47].
The protocol is described in S1 and S6.
2.12. Induction of Adoptive Transfer Colitis Using CD4+
CD25−CD45RBhigh T Cells. The protocol is described in S1
and S6.
2.13. Induction of Piroxicam-Accelerated Colitis (PAC) in
IL-10−/− Mice. Piroxicam-accelerated colitis (PAC) was per-
formed as previously described [48, 49].
The protocol is described in S1 and S6.
2.14. Induction of DSS Colitis. Induction of dextran sulphate
sodium (DSS) colitis was performed as previously described
[50, 51]. The protocol is described in S1 and S6.
2.15. Monitoring of Disease in Mice. Body weight was moni-
tored three times weekly, and the mice were sacriﬁced if they
lost more than 20% of their initial body weight. Faecal consis-
tency was evaluated before the start of the treatment and
subsequently 3 times a week using a semiquantitative score
(normal stool = 0; slightly soft = 1; soft but formed=2; not
formed=3; and liquid stools or no faeces in colon at sacri-
ﬁce = 4). Disease activity index (DAI) score was calculated
as previously described [48, 49, 51].
2.16. Collection of Serum and WBC Counts from Mice. Dur-
ing the experiment, the mice were anesthetized with isoﬂur-
ane, and blood from the periorbital venous plexus was
collected in EDTA-containing tubes for white blood cell
(WBC) counts, FACS analysis, and exposure. The number
of WBC per liter was analysed in samples (20μl) of EDTA-
stabilized peripheral whole blood, using a Medonic CA
620 (Boule Nordic, Denmark) blood analysis apparatus
according to the manufacturer’s instructions. Serum samples
were collected directly in microtainer SST tubes (BD, US).
The isolated serum samples were then transferred to micro-
nic tubes and stored at −80°C.
2.17. Flow Cytometry of Blood Samples from Mice. The ﬂow
cytometry analysis of mouse blood samples was performed
as described in S1 and S6.
2.18. Exposure and Pharmacokinetics in Mice. Exposure and
pharmacokinetic analysis was performed as described in S1
and S6.
2.19. Endoscopic Analysis on Mice. Mice were anaesthetized
with isoﬂurane and placed on the back. A rigid telescope
(HOPKINS straight forward, 0°) was connected to a light
source/air pump (Xenon 175) and a camera (Telecam SL)
all purchased from Karl Storz (Tuttlingen, Germany), as well
as a monitor (Sony Triniton) and a video recorder (SCB aida
DVD, Karl Storz) as described by Becker et al. [52]. The
endoscope was coated with a lubricant containing lidocaine
hydrochloride (Farco-pharma, Köln, Germany) and intro-
duced via the anus into the distal 4 cm of the colon. The eval-
uation of the colonoscopy ﬁndings was done by two blinded
observers using the Murine endoscopic index of colitis sever-
ity (MEICS) score as previously described in [52].
2.20. Post Mortem Analyses on Mouse Tissue. Mice were
sacriﬁced by cervical dislocation, and the caecum, colon,
and rectum were excised. The length of the colon was mea-
sured from the caeco-colonic junction to the anus. The colon
was rinsed with PBS and weighed. The colonic weight : length
(W :L) ratio (cm/g) was used as a macroscopic, objective
parameter to verify the presence of established colitis, since
it is known to correlate with the histology score [48]. The
proximal 1/3 of the colon was removed, and the remaining
2/3 of the colon was bisected or trisected longitudinally.
The dissected colon biopsies were processed for histological
analysis, qPCR, and cytokine/chemokine proﬁling.
2.21. Histological Analysis on Mouse Tissue. Histological
analyses on mouse tissues were performed as described in
details in S1 and S6.
The severity of the histopathological lesions of colon seg-
ments was examined in a blinded manner, using the criteria
previously described in [46, 48, 51, 53].
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2.22. IL-21 Intracellular Cytokine Staining of Mesenteric
Lymph Node (mesLN) CD4+ T Cells. On day 7, 16, 29, and
38 post cell transfer, mesenteric lymph node (mesLNs) and
colons were aseptically removed from 5 mice per time point.
Three (3) naïve BALB/c mice were included as controls.
Restimulation mesLN lymphocytes or LPLs were stimulated
for 4 h at 37°C/5% CO2 with PMA/ionomycin in vitro in
the presence of GolgiSTOP (w/monensin) and GolgiPLUG
(w/Brefeldin A). Following stimulation, cells were surface
stained with murine Fc Block (α-CD16/32) followed by sur-
face staining with the antibodies indicated in the following:
anti-mouse CD45 Qdot605, anti-mouse TCRb FITC, anti-
mouse CD4 PE, and anti-mouse CD8 Paciﬁc Blue, NEAR-
IR (APC-Cy7). Subsequently, the cells were washed and ﬁxed
in 4% PFA. The ﬁxed cells were permeabilized by Perm/
Wash buﬀer. Hereafter, either anti-mouse IL-21 or mouse
IgG1 conjugated to AlexaFlour647 was added.
2.23. In Vitro Stimulation of mesLN CD4+ T Cells with IL-21.
mesLN was aseptically removed from mice with AdTr and
passed through a 70μmcell strainer to obtain a single-cell sus-
pension. CD4+ T cells were obtained using a murine CD4-
negative section kit (Miltenyi Biotec Norden, Copenhagen,
Denmark). The resulting cells were cultured for 72 h in RPMI
medium 1640 with FBS (10%) and penicillin/streptomycin
(1%) in the presence of immobilized anti-CD3 (0–25 ng/ml)
(clone 145-2c11; eBioscience, San Diego, CA, USA) and
rmIL-21 (0–50 ng/ml; R&D Systems, Abingdon, UK) as
well as recombinant mouse anti-mouse IL-21s mAb or
mouse IgG1 (both 5μg/ml). Supernatants were subsequently
collected for the analysis by a premixed mouse cytokine/
chemokine multiplex antibody detection system (Milliplex,
Millipore, and Billerica, MA, USA).
2.24. Statistical Analyses
2.24.1. Human Study. The semiquantitative scoring of the
immunohistochemical data for IL-21R protein expression
was analysed by Mann–Whitney’s two-tailed nonparamet-
ric t-test in GraphPad Prism 5, and p < 0 05 was consid-
ered signiﬁcant.
2.24.2. Experimental Mouse Studies. In the experimental
colitis studies, GraphPad Prism version 6.0 was used for all
statistical analyses. The statistical signiﬁcance of diﬀerences
between normally distributed, parametric data from the two
groups was evaluated using unpaired Student’s t-test. The
comparison of nonparametric, non-Gaussian distributed
data from the two groups was performed using a nonpara-
metric Mann–Whitney U test. The statistical signiﬁcance
between more than two groups was evaluated by a one-way
ANOVA or Kruskal–Wallis test with Holm-Sidak’s or
Dunn’s multiple comparison test, respectively. Prophylactic
treatment studies were evaluated by two-sided tests, whereas
therapeutic studies were evaluated by one-sided tests.
3. Results
IL-21 and IL-21R mRNA and protein expression analyses
were assessed on frozen OCT-embedded and ﬁxed paraﬃn-
embedded intestinal samples from non-IBD controls histo-
pathologically within normal limits and from patients with
CD, respectively. The intestinal types included in each study
are listed in Table 1.
3.1. IL-21 and IL-21R Expression in the Intestine from
Patients with CD. As summarized in Table 1, IL-21 and IL-
21R mRNA and protein-expressing cells were observed in
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 1: IL-21 mRNA expression in the small intestine from
patients with Crohn’s disease. In situ hybridization for IL-21
mRNA expression using the IL-21as (a, b, c, d, e, f) and IL-21s
(g, h) probes on the small intestine from patients with CD
(patient 1 (a–d), patient 2 (e-f)). IL-21 mRNA expressions are
seen as white and black granules, in few isolated cells within the
IEL compartment in (a) and (b) (white and black arrowheads,
resp.). IL-21 mRNA-expressing cells are seen as white and black
granules in lymphoid aggregates in the mucosa (white and black
arrows in (a) and (b), resp.), in isolated lymphoid follicles in the
submucosa (white and black arrows in (c) and (d), resp.), and in
the muscularis externa (white and black arrows in (e) and (f),
resp.). No speciﬁc reaction was observed with the IL-21s probe
(g, h). The sections were counterstained with haematoxylin/eosin.
Bars: 50μm (a–e).
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the mucosa and submucosa from non-IBD intestinal samples
within normal limits. In patients with CD, the IL-21 and IL-
21R mRNA-expressing cells were generally observed as
solitary cells in the lamina propria (Figures 1(a) and 1(b)
and Figures 2(a), 2(b), 2(e), and 2(f), resp.), in the follicle-
associated epithelium (FAE) and isolated (solitary) lymphoid
follicles (ILF), Peyer’s patches (ileum), and colonic-isolated
lymphoid follicles (colon) of the submucosa (Figures 1(c)
and 1(d) and Figures 2(c) and 2(g), resp.), and in lymphoid
aggregates of the muscularis externa (Figures 1(e) and 1(f)).
No reactivity was observed with the IL-21 and IL-21R sense
probes (Figures 1(g) and1(h) andFigures 2(d) and2(h), resp.).
IL-21R mRNA expression in the intraepithelial lymphocyte
(IEL) compartment (e.g., surface epithelium including intrae-
pithelial lymphocytes) could not be clearly demonstrated.
As summarized in Table 2, IL-21 and IL-21R immunopo-
sitive immune cells were present in intestinal non-IBD sam-
ples within normal limits in the mucosa and submucosa. In
patients with CD, additional expression was observed within
lymphoid aggregates of the submucosa and in the muscularis
externa, with abundant expression in GCs. Thus, the general
compartmentalization of IL-21 and IL-21R immunopositive
cells resembled that described for IL-21 and IL-21R mRNA
expressing cells, that is, within the IEL compartment, in
follicle-associated epithelium and as solitary cells in the lam-
ina propria of the mucosa (Figures 3(a) and 3(b)), in Peyer’s
patches/colonic-isolated lymphoid follicles and solitary cells
of the submucosa (Figures 3(c) and 3(d)), and in lymphoid
aggregates of the muscularis externa (Figures 3(e) and 3(f)).
Finally, IL-21R immunopositive cells were generally more
abundantly present than IL-21 immunopositive cells. These
IL-21 immunopositive cells were present within the same
areas as IL-21R immunopositive cells throughout the diﬀerent
immune compartments of the intestine from patients with
CD. No immunoreactivity was observed with the isotype-
speciﬁc control antibody (Figures 3(g) and 3(h)).
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Figure 2: IL-21R mRNA expression in the colon from a patient with Crohn’s disease. IL-21R mRNA expression was assessed by in situ
hybridization using the IL-21Ras (a, b, c, e, f, g) and IL-21Rs (d, h) probes on intestines from patients with CD. Colonic IL-21R
mRNA-expressing cells are seen as white and black granules in an isolated lymphoid aggregate in the submucosa (white arrow and black
arrow in (a) and (e), resp.). IL-21R mRNA expression is seen in the isolated follicle-associated epithelium of the mucosa (white arrow and
black arrow in (b) and (f), resp.) and in isolated lymphoid follicles in the submucosa penetrating into the muscularis externa (white and
black arrows in c and g, resp.). No speciﬁc reaction was observed with the IL-21Rs probe (d, h). The sections were counterstained with
haematoxylin/eosin. M: mucosa; ME: muscularis externa; SM: submucosa. Bars: 200μm (a, c, d, e, g, h) and 50 μm (b, f).
Table 2: Summary of IL-21 and IL-21R expression in the intestine from patients with Crohn’s disease.
Diagnosis Target Method Entire intestine Mucosa Submucosa Muscularis externa
Normal non-IBD controls
IL-21 ISH (mRNA) 10/15 8/15 7/15 0/15
IL-21R ISH (mRNA) 11/17 9/17 8/17 0/17
IL-21 IHC (protein) 5/5 5/5 1/5 0/5
IL-21R IHC (protein) 18/18 18/18 15/18 1/18
Crohn’s disease
IL-21 ISH (mRNA) 10/13 9/13 10/13 5/13
IL-21R ISH (mRNA) 12/12 11/12 8/12 2/12
IL-21 IHC (protein) 6/6 3/6 5/6 4/6
IL-21R IHC (protein) 17/17 17/17 17/17 9/17
A positive patient is identiﬁed as having IL-21/IL-21R-expressing cells. Numbers of IL-21/IL-21R-positive patients/total number of patients included in the
study are listed. IHC: immunohistochemistry; ISH: in situ hybridization.
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The semiquantitative analysis was performed on mucosa-
associated lymphoid tissues identiﬁed according to the revised
nomenclature assigned by Brandtzaeg et al. [54] and semi-
quantitatively scored as described in Materials and Methods.
Based on the semiquantitative score the IL-21R was
signiﬁcantly highly expressed (p < 0 05) in the intestine
from patients with CD compared to non-IBD control
intestinal samples within normal limits (Figure 4(a)). The
IL-21R expression did not reach signiﬁcance in the mucosa
(p = 0 47) (Figure 4(b)), but did show a signiﬁcant diﬀerence
in the submucosa (p < 0 01) (Figure 4(c)) and muscularis
externa (p < 0 01) (Figure 4(d)).
There was no signiﬁcant diﬀerence in the IL-21R expres-
sion in the IEL compartment in samples from patients with
CD compared to non-IBD controls (data not shown). The
study on IL-21 protein expression was not powered to per-
form a semiquantitative analysis of IL-21 expression.
3.2. Characterization of IL-21R-Positive Cells in the Intestine
from Patients with Crohn’s Disease. Double immunostaining
for the characterization of IL-21R immunopositive (IL-21R+)
cells in the intestine from non-IBD controls and patients with
CD was performed with markers for T cells (CD3), B cells
(CD20), plasma cells (CD138), or macrophages (CD68).
IL-21R+CD3+ T cells were present in the mucosa, submu-
cosa (Figures 5(a)–5(c)), andmuscularis externa, interspersed
in general in the diﬀerent intestinal layers and in particular
within lymphoid aggregates. Likewise, IL-21R+CD20+ B cells
were found in the mucosa, lymphoid aggregates, and partic-
ularly GCs of the submucosa and muscularis externa from
patients with CD (Figures 5(d)–5(f)). In addition, IL-
21R+CD138+ plasma cells were observed only in the mucosa
in the normal intestine (data not shown), whereas CD IL-
21R+ plasma cells were also present in lymphoid aggregates
of the submucosa (Figures 5(g)–5(i)) and muscularis
externa. Finally, IL-21R+CD68+ macrophages were present
in the mucosa and lymphoid aggregates of the submucosa
(Figures 5(j)–5(l)) and muscularis externa from patients
with CD as well as in non-IBD controls (data not shown).
The study was not powered to perform a quantitative analy-
sis of the individual subsets of IL-21R+ cells.
3.3. IL-21-Producing CD4+ T Cells Are Upregulated in the
CD4+CD25− T Cell Adoptive Transfer (AdTr) Colitis Model.
Because IL-21 is reported to be produced by both human
and mouse Th17 cells [6, 24] and since Th17 cells have been
shown to be involved in adoptive transfer colitis, we initially
focused on the CD4+CD25− T cell transfer model of colitis.
Moreover, before treatment, studies were initiated; target
validation was conducted to describe the dynamics of IL-21
protein expression by CD4+ T cells during the development
of colitis.
The percentage of IL-21+CD4+ T cells was shown to
increase over time, in both the mesLN and the lamina propria
(Figures 6(a) and 6(b)). As well, the percentage of mesLN IL-
21+CD4+ cells correlated with the degree of body weight
change in individual mice with colitis, indicating that IL-21
may be involved in colonic disease development in this
model (Figure 6(c)).
3.4. A Mouse Anti-Mouse IL-21 mAb Inhibits IL-21-Driven
Cytokine and Chemokine Production from mesLN CD4+ T
Cells. Next, we tested whether a neutralizing mouse anti-
mouse IL-21 monoclonal antibody (mAb) could neutralize
anti-CD3 or anti-CD3/IL-21-induced production of proin-
ﬂammatory cytokines and chemokines from mesLN CD4+
T cells isolated from mice with colitis (Figures 7(a)–7(g)).
Neutralization of endogenous IL-21 only induced minor
decreases in cytokine and chemokine production follo-
winganti-CD3 stimulation. The only signiﬁcantly regulated
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Figure 3: IL-21 and IL-21R protein expression in the intestine
from patients with Crohn’s disease. Immunohistochemical
staining of IL-21 (a, c, e) and IL-21R (b, d, f) in the colon from
patients with CD. IgG1 isotype-speciﬁc control antibody is shown
in (g) and (h). IL-21+ cells (arrows in (a), (c), and (e)) and IL-21R+
cells (arrows in (b), (d), and (f)) are seen as solitary cells in the
lamina propria of the mucosa (a, b), lymphoid aggregates of the
submucosa (c and d), and muscularis externa (e, f), respectively.
No reaction was observed with the IgG1 control antibody (g, h).
Nuclei (in blue) were counterstained with haematoxylin. Bars:
50 μm (a–h).
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chemokine was CCL5 (p < 0 009) (Figure 7(f)). When exoge-
nous IL-21 was added, the eﬀect of the blocking anti-IL-21
mAb was much more pronounced with a signiﬁcant inhibi-
tion of IFN-γ, TNF-α, GM-CSF, CCL3, IL-17, CCL5, IL-4,
and CCL-4 production (Figures 7(a)–7(g)). No signiﬁcant
eﬀect was seen on IL-2, IL-5, and IL-6 (data not shown).
3.5. Pharmacokinetics of Anti-IL-21 mAb in Mice. In a pilot
study, we determined the exposure and the pharmacokinetics
of our mouse anti-IL-21 mAb and performed modelling
using a 1-compartment model. Exposure from AdTr colitis
mice using two selected doses of mouse anti-mouse IL-21
(3.3mg/kg and 25mg/kg) was compared with the simulated
exposure levels based on pharmacokinetics in healthy NMRI
mice. At both doses (3.3 and 25mg/kg), circulating unbound
mouse anti-IL-21 mAb was detected (Figure S1) and
matched the simulated exposure. The 25mg/kg dose
interval was selected in subsequent studies in order to have
the highest possible peripheral exposure.
3.6. Prophylactic Treatment with Anti-IL-21 mAbAmeliorates
CD4+CD25− T Cell AdTr Colitis. Next, we wanted to assess
whether treatment with 25mg/kg anti-IL-21 mAb could
prevent adoptive transfer colitis, compared to mice treated
with mIgG1.
The change in body weight over the course of the experi-
ment is shown in Figure 8(a). As previously described [46, 47],
mice treated with mIgG1 started to lose body weight in the
3rd-4th week following transfer. In comparison, mice treated
with anti-IL-21 mAb showed some weight loss in week 3,
but stabilized at a level above the isotype control. The dif-
ference did not reach statistical signiﬁcance (P < 0 13) at
study termination.
Blood samples were obtained on day 28 in order to
evaluate whether anti-IL-21 merely prevents T cell prolifera-
tion. Mice treated with anti-IL-21 mAb did not show any
reduction in WBC counts compared to control treated mice
(Figure 8(b)). Neither analysis of the peripheral blood did
reveal any changes in CD4+ T cell frequencies (Figure 8(c)).
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Figure 4: Semiquantitative analysis of the IL-21R protein expression in Crohn’s disease. IL-21R protein expression was investigated by
immunohistochemistry. The mucosa-associated lymphoid compartments were individually scored. Mucosa (M): intraepithelial
lymphocyte compartment (surface epithelium), lamina propria, and follicle-associated epithelium. Submucosa (SM): isolated (solitary)
lymphoid follicles (IEL), Peyer’s patches (ileum)/colonic IEL (colon), and isolated inﬁltrating lymphocytes. Muscularis externa (ME): IELs
and isolated inﬁltrating lymphocytes. Each compartment was scored on a scale from 0 to 4: 0, no; 1, few; 2 moderate; 3, many; and 4,
abundant numbers of IL-21R+ cells. An accumulated score was calculated for each intestinal layer (M, SM, ME) and in total (M+ SM
+ME) for the entire intestine. Max score: M and SM=12; ME= 8; M+ SM+ME= 32. Green closed squares and red closed circles
represent colon samples, whereas green open squares and red open circles represent small intestinal samples, from normal non-IBD
controls and patients with CD, respectively. The data were analysed by Mann–Whitney’s two-tailed nonparametric t-test in GraphPad
Prism 5, and p < 0 05 was considered signiﬁcant.
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Figure 5: Continued.
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Figure 5: The IL-21R is expressed by T cells, B cells, plasma cells, and macrophages in the intestine from patients with Crohn’s disease.
Double immunoﬂuorescence staining for the IL-21R (red signal in (a), (d), (g), and (j)), CD3+ T cells (green signal in (b)), CD20+ B cells
(green signal in (e)), CD138+ plasma cells (green signal in (h)), and CD68+ macrophages (green signal in (k)) of the intestine from
patients with CD analysed by confocal microscopy. Merged images of (a, b), (d, e), (g, h), and (j, k) are seen in (c), (f), (i), and (l),
respectively. IL-21R+ T cells, plasma cells, and macrophages are seen in lymphoid aggregates of the submucosa, and IL-21R+ B cells are
seen in the lymphoid aggregate of the muscularis externa. The nuclei (in blue) were counterstained with Hoechst. Bars: 10μm (c, f, i, l).
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In the AdTr colitis model, the disease can be associated with
thickening of the colon wall. This is related to the inﬁltration
of donor T cells and the resulting host inﬂammatory response.
The host response includes inﬁltration of additional inﬂam-
matory cells (e.g., neutrophils and macrophages), vascular
leakage resulting in intestinal oedema, and varying degrees
of mucosal epithelial hyperplasia, all of which contribute to
the thickness of the wall of the colon. In turn, there is a com-
pensatory shortening of the colon. The ratio of colon weight
(W) to length (L) provides a colon thickening index, which
correlates with colitis severity and histopathology.
Mice treatedwithmouse anti-IL-21mAb had a signiﬁcant
reduction in the colonW :L ratio, compared tomIgG1-treated
mice (P < 0 02) (Figure 8(d)).
To acquire a translational clinical endpoint, a 2mm endo-
scope was introduced via the mouse anus. Endoscopic pic-
tures were obtained to allow the monitoring and grading of
inﬂammation. The grading uses themurine endoscopic index
of colitis severity (MEICS) score encompassing (thickening of
the colon, changes of vascular pattern, visible ﬁbrin, granular-
ity of mucosal surface, and stool consistency). Mice treated
with the anti-IL-21 mAb had a signiﬁcant reduction in their
endoscopic score on day 28, compared to mice treated with
mIgG1 (P < 0 01) (Figures 8(e) and 8(f)).
A signiﬁcant reduction in the histopathology score was
also observed in mice treated with anti-IL-21 mAb com-
pared to mIgG1 (Figures 9(a)–9(c)). The analysis of the
inﬂammatory subsets by immunohistochemistry revealed
that only calprotectin-positive cells (neutrophils and macro-
phages) were signiﬁcantly reduced (P < 0 006), whereas no
signiﬁcant eﬀect could be detected in the CD3 density
(Figures 9(g)–9(i) and Figures 9(d)–9(f), resp.). We also
evaluated changes in mRNA transcripts (Th1, Th2, Th17,
and Treg) in colonic biopsies. The only transcript that was
signiﬁcantly downregulated following the anti-IL-21 mAb
treatment was GATA3 (Supplementary Figure 2).
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Figure 6: IL-21 expression is upregulated in mesenteric lymph node and lamina propria CD4+ T cells frommice with AdTr colitis. Frequency
of CD4+IL-21+-positive T cells in the lamina propria on days 7, 17, 29, and 38 versus BALB/c controls (a). Frequency of CD4+IL-21+-positive
T cells in mesenteric lymph nodes on days 7, 17, 29, and 38 versus BALB/c controls (b). Frequency of CD4+IL-21+-positive T cells versus delta
weight loss in mice with AdTr (c).
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Figure 7: Cytokine and chemokine secretion frommesenteric lymph CD4+ T cells stimulated with anti-CD3 and/or IL-21. CD4+ T cells were
isolated from mesenteric lymph nodes from mice with AdTr colitis. IFN-γ (a), TNF-α (b), GM-CSF (c), CCL3 (d), IL-17 (e), CCL5 (f), IL-4
(g), and CCL4 (h) secretion from in vitro stimulated CD4+ T cells. Cells were stimulated with plate bound anti-CD3 and/or IL-21 in
combination with anti-IL-21 or isotype control (mouse IgG1).
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3.7. Interventive Treatment with Anti-IL-21 mAb Has a
Moderate Eﬀect on Disease Parameters in the CD4+CD25−
T Cell AdTr Model. We have previously shown that mild
to moderate colonic inﬂammation is present at day 21
[47]. Thus, we randomized our treatment groups according
to weight on day 21. Anti-IL-21 mAb treatment had a sig-
niﬁcant eﬀect on body weight loss over the treatment
period (Figure 10(a)). However, even though there was a
tendency to lower colonic disease score in mice treated
with anti-IL-21 mAb, no signiﬁcant eﬀect could be detected
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Figure 8: Prophylactic treatment of AdTr mice with anti-IL-21 mAb ameliorates colitis. Open circles indicate individual anti-IL-21 mAb-
treated mice, black squares indicate individual mIgG1-treated mice, and grey triangles indicate individual control SCID mice. Delta body
weight change over time (a). White blood cell count on day 28 (b). Frequency of CD4+TCRb+ T cell in blood on day 28 (c). Colon
weight : length ratio (d). Endoscopic score encompassing (thickening of the colon, changes of vascular pattern, visible ﬁbrin, granularity of
mucosal surface, and stool consistency) on day 28 (e). Pictures showing representing images of the colon in anti-IL-21 mAb-treated mice
(left), mIgG1-treated mice (middle), and SCID control mice (right) (f).
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on WBC counts, CD4+TCR+ T cell frequency, colon W :L
ratio, and endoscopic score (Figures 10(b)–10(e)). Colonic
inﬂammation was further assessed by the evaluation of
the histopathology score, density of CD3, and calprotectin
staining. Similar to the prophylactic study, both histopathol-
ogy score (Figures 11(a)–11(c)) and calprotectin density
(Figures 11(g)–11(i)) were signiﬁcantly reduced following
anti-IL-21 mAb treatment, whereas no signiﬁcant eﬀect on
CD3 density could be detected (Figures 11(d)–11(f)). Cyto-
kine and chemokine proﬁling of colon biopsies from mice
conﬁrmed a signiﬁcant interventive treatment eﬀect of anti-
IL-21 mAb on chemokine and Th17-related parameters
(KC, CCL3, CCL5, IL-17, TNFα, IFN-γ, CCL2, and IP-10)
(Figure 12). However, TNFα, IFN-γ, CCL2, and IP-10 were
only borderline signiﬁcant and determined by few mice with
high colonic levels. Four SCID control mice were included
in the analysis to show the cytokine and chemokine back-
ground level. In the isotype-treated mice all cytokines and
chemokines besides CCL3 were elevated compared to SCID
control mice.
No signiﬁcant treatment eﬀect was observed for IL-13,
IL-10, IL-5, IL-6, IL-9, IL-12p70, IL-1β, IL-7, IL-2, IL-4,
IL-5, and G-CSF (data not shown).
3.8. Ablation of IL-21 Signalling Ameliorated Colitis in the
CD4+CD45RBhigh Model. Since absolute neutralization of
cytokine signalling on CD4+ T cells may be diﬃcult to achieve
with an antibody, we tested whether naïve CD4+ T cells would
require the IL-21R to develop chronic mucosal inﬂammation
in the CD4+CD45RBhigh model using B6.129S6-RAG2−/−
mice as recipients. In short, no eﬀect was detected on body
weight change, but mice transferred with CD4+CD45RBhigh
IL-21R−/− T cells had a signiﬁcantly lower colon W :L ratio
as well as reduced numbers of granulocytes in the blood, com-
pared to mice transferred with CD4+CD45RBhighIL-21R+/+ T
cells (Figures 13(a)–13(c)). Moreover, no signiﬁcant diﬀer-
ence between Tregs expressing the IL-21R and Tregs lacking
the IL-21R could be detected in cotransfer experiments. How-
ever, CD4+IL-21R+/+ Tregs did reduce the colon W :L ratio
signiﬁcantly when compared to mice only transferred with
CD4+CD45RBhighIL-21R+/+ T cells (Figure 13(c)).
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Figure 9: Prophylactic treatment with anti-IL-21 mAb reduces colonic transformation and neutrophil inﬁltration. All images are from
animals representing mean values of the individual analyses. (a), (d), and (g) show the colon of AdTr mice treated with anti-IL-21 mAb,
and (b), (e), and (h) show animals treated with the control mIgG1 antibody. (a, b) HE staining showing the hyperplasia of the mucosa
signiﬁcantly reduced (p < 0 02) by treatment with anti-IL-21 as seen in the histopathological analysis (c). (d, e) Immunohistochemical
demonstration of CD3-positive T cells (in brown) in the mucosa and submucosa. (f) The density- (in %) positive T cells quantiﬁed by
digital image analysis did not reach signiﬁcance. (g, h) Immunohistochemical demonstration of calprotectin-positive neutrophils (in
brown). (i) The density (in %) calprotectin-positive neutrophils and macrophages quantiﬁed by digital image analysis were signiﬁcantly
reduced (p < 0 006) by treatment with anti-IL-21. Nuclei (in blue) were counterstained with haematoxylin. Bars: 200 μm (a, b, d, e, g, h).
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3.9. Prophylactic Treatment with Anti-IL-21 Has No
Treatment Eﬀect in the Piroxicam-Accelerated Colitis Mouse
Model. Anti-IL-21 mAb treatment was also evaluated in the
piroxicam-accelerated colitis (PAC) mouse model. This
model is more acute and is not directly driven by CD4+ T
cells [48, 49].
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Figure 10: Interventive treatment of AdTr mice with anti-IL-21 mAb. Open circles indicate individual anti-IL-21 mAb-treated mice, black
squares indicate individual mIgG1-treated mice, and grey triangles indicate individual control SCID mice. Delta body weight change over
time (days) (a). White blood cell count on days 21 and 34 (b). Frequency of CD4+TCRb+ T cells in blood on day 34 (c). Colon
weight : length ratio (d). Endoscopic score encompassing (thickening of the colon, changes of vascular pattern, visible ﬁbrin, granularity of
mucosal surface, and stool consistency) on days 21, 34, and 47 (e).
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First, the frequency of CD4+ T cells expressing IL-21 was
determined in mesLN. As seen in Figure 14(a), the percent-
age of IL-21+CD4+ T cells was signiﬁcantly elevated in PAC
IL-10 k.o. compared to IL-10 k.o. littermates. Still, the per-
centage of IL-21+CD4+ T cells was lower compared to the
AdTr colitis model (Figure 6). Following prophylactic treat-
ment with anti-IL-21 mAb, no signiﬁcant treatment eﬀect
could be observed on systemic parameters. At day 18, the
mean body weight change of anti-IL-21 mAb and mIgG1-
treated mice was minus 5%, and no signiﬁcant diﬀerence in
weight change could be observed (Figure 14(c)). The sys-
temic serum level of the acute phase protein (haptoglobin)
level at day 11 was unchanged (Figure 14(d)). As well, anti-
IL-21 mAb treatment had no eﬀect on colonic parameters
such as the colon W :L ratio at termination or endoscopic
score day 12 (Figures 14(e) and 14(f)). The only indication
of a positive treatment eﬀect was a signiﬁcant reduction in
colonic MPO levels (Figure 14(b)). Indicating a potential
eﬀect on neutrophils and macrophages.
4. Discussion
IL-21 has been shown to be upregulated in the intestine from
patients with IBD in several studies by diﬀerent methods
such as Western blotting of total protein extracts from tissue
specimens, culture of lamina propria mononuclear cells
(LPMCs) followed by ELISA on supernatants, intracellular
ﬂow cytometry on LPMCs [22, 55, 56], and immunohisto-
chemistry of mucosal biopsies [57]. In the present study,
using resected intestinal human samples, the presence of
IL-21 mRNA and protein-expressing cells was described in
diﬀerent immune cell compartments in the intestine from
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Figure 11: Interventive treatment with anti-IL-21 mAb reduces colonic transformation and neutrophil inﬁltration. All images are from
animals representing mean values of the individual analyses. (a), (d), and (g) show the colon of AdTr mice treated with anti-IL-21 mAb
and (b), (e), and (h) show animals treated with the control mIgG1 antibody. (a, b) HE staining showing the hyperplasia of the mucosa
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patients with CD. IL-21 mRNA was primarily expressed by
solitary cells in the IEL compartment, lamina propria, and
follicle-associated epithelium of the mucosa, in isolated
lymphoid follicles in the submucosa as well as in inﬁltrates
in the muscularis externa.
Upregulation of the IL-21R in the intestine from patients
with IBD has likewise been demonstrated by diﬀerent groups
using immunohistochemistry [35, 56]. In the present study,
these data were conﬁrmed, as the IL-21R was signiﬁcantly
upregulated in the intestine from patients with CD compared
to non-IBD control samples. Moreover, the IL-21R mRNA
expression was similar to the IL-21R protein expression
pattern in the immune cell compartment characteristic of
the intestinal wall. Speciﬁcally, IL-21R mRNA and protein
were expressed by solitary immune cells in the lamina pro-
pria and follicle-associated epithelium of the mucosa, in iso-
lated lymphoid follicles in submucosa, as well as in cellular
inﬁltrates of the muscularis externa. Moreover, increased
IL-21R protein expression was restricted to the submucosa
and muscularis externa. Thus, IL-21 and IL-21R expression
followed the histopathological hallmark of CD, that is, the
transmural inﬂammation that was observed in the resected
material investigated herein as compared to studies per-
formed on mucosal biopsies [35, 56, 57]. Furthermore, we
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identiﬁed the IL-21R+ cells as the subsets of T cells, B cells,
plasma cells, and macrophages; however, the study was not
powered to detailed quantitative analyses.
In this context, one may speculate that the expression of
the IL-21R on CD20+ B cells, CD138+ plasma cells, and the
CD68+ macrophages directly and/or indirectly has an eﬀect
on T cell activation, B cell maturation, and immunoglobulin
production from plasma cells. Whether a similar situation
applies to patients with UC remains to be examined in full
size biopsies. However, it may be hypothesized that the eﬀect
of IL-21 in patients with UC is related to the cytokine pleio-
tropic eﬀect on neutrophils and/or macrophages, a hallmark
for the inﬂammation in these patients.
Previous studies have shown that mice lacking IL-21 are
unable to upregulate Th17-associated molecules during
experimental colitis and are largely protected from DSS-
induced colitis [31, 34, 58, 59]. Similarly, immunodeﬁcient
mice adoptively transferred with CD4+IL-21−/− T cells
develop less severe colitis [60, 61], and mice treated in a
prophylactic setup with a neutralizing IL-21R/Fc fusion
protein or anti-IL-21 mAb are protected from both DSS
and TNBS-induced colitis [31, 58, 59]. In our AdTr study
with CD4+CD25− T cells, we observed a clear production
of IL-21 from the lamina propria and mesenteric lymph
node CD4+ T cells. Moreover, we observed a reduction of
colonic inﬂammation following both prophylactic and
interventive treatments with 25mg/kg anti-IL-21 mAb. This
treatment eﬀect was not associated with a noticeable
reduction in WBC, CD4+ T cell frequency, or colonic
CD3-inﬁltrating T cells, suggesting that the eﬀects of neu-
tralizing IL-21 in this model may not depend on the pre-
vention of T cell proliferation or migration. However, we
observed a reduction in colonic calprotectin (marker of
neutrophils), several chemokines, and proinﬂammatory
cytokines, supporting the idea that IL-21 neutralization
in vivo not only aﬀects CD4+ T cell diﬀerentiation but
also regulates neutrophil inﬁltration through direct or
indirect mechanisms. To further dissect the importance
of IL-21 signalling in innate lymphoid cells and nonim-
mune cells, future studies should investigate the in vivo
eﬀects of transferring CD4+ T cells to IL-21R−/−Rag2−/−
recipient mice. In our piroxicam-accelerated colitis study,
where colitis symptoms are more acute and not directly
driven by CD4 T cells [48, 49], we did not observe any pro-
tective eﬀect of IL-21 neutralization. However, if CD4+ T
cells are the primary producer of IL-21, this may not be
surprising.
The underlying mechanism of IL-21 signalling in
experimental colitis is still unclear. Most groups describe
a downregulation of Th17 cells and associated molecules
[31, 34, 58, 59], while other groups report that IL-21 is
not essential for Th17 cell development [60–62].
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Weexplored the direct eﬀect of IL-21 signalling inCD4+T
cells by transferring either CD45RBhighIL-21R−/− CD4+ T
cells or CD45RBhighIL-21R+/+ CD4 T cells to Rag2 k.o. mice.
This concept is clearly diﬀerent from transferring CD4+ T
cells lacking IL-21 or IL-21 neutralization by treatment, since
other cell types, for example, innate lymphoid cells or ﬁbro-
blasts may respond to IL-21 secreted from the CD4+IL-
21R−/− T cells. In our study, we observed less severe colitis in
Rag2 k.o. mice transferred with CD45RBhighIL-21R−/− CD4+
T cells compared with mice transferred with CD45RBhighIL-
21R+/+ CD4+T cells. In addition,mesLNCD4+T cells isolated
from mice with colitis responded with excessive production
of proinﬂammatory cytokines and chemokines following
stimulation with exogenous IL-21. The observation sup-
ports that IL-21 signalling may play a part in the initial
development and diﬀerentiation of pathogenic CD4+ T cells.
However, we could not detect a marked reduction in proin-
ﬂammatory cytokine or chemokine production following
in vitro neutralization of endogenous IL-21 production by
mesLN CD4+ T cells. Thus, only high IL-21 levels seem to
mediate the secretory eﬀect. In addition, we could not detect
any signiﬁcant changes in Th17, Th1, or Treg transcription
factors in colonic biopsies; only Th2 transcripts were down-
regulated by anti-IL-21 mAb treatment.
Moreover, several studies suggest that IL-21 mediates
inhibitory eﬀects of peripheral diﬀerentiation of Tregs and
makes CD4+ T cells resistant to Tregs-mediated immune
suppression [34, 63]. However, in our CD45RBhighCD25+-
CD4+ T cell transfer study, only minor eﬀects of IL-21R abla-
tion could be detected on Treg frequency or in vivo
suppressive function. We speculate that IL-21 in our model
primarily aﬀects the diﬀerentiation of Th17 in mesLN rather
than aﬀecting Tregs directly.
Recently, Wang et al. [64] reported that IL-21/IL-21R sig-
nalling may actually suppress intestinal inﬂammation induced
by DSS through regulation of Th responses. Still, in most stud-
ies, IL-21−/− mice have been reported to be protected from
DSS-induced colitis [31, 34, 58, 59]. In our facility, IL-21R−/−
mice are not protected from DSS-induced colitis neither in
an acute nor in a chronic setup (Supplementary Figures 3
and 4). The discrepancy between colitis studies with IL-21 or
IL-21R−/− mice may be due to variability in microﬂora
between laboratories, T cell dependency in the model setup,
or a consequence of transcriptional changes in the areas
around the targeted gene in the k.o. mice. However, it also
highlights the complex biology associated with IL-21 signalling.
IL-21 is overproduced in many chronic inﬂammatory
disorders, and studies in experimental models indicate that
IL-21 plays an important role in sustaining tissue damage.
Moreover, since IL-21 is a pleiotropic cytokine and since
CD most likely is caused by multiple immunological subsets,
the stimulatory role of IL-21 on non-CD4+ T cells, for
example, neutrophils, IgA-producing B cells, ﬁbroblasts,
and macrophages, should be further investigated.
Conflicts of Interest
All authors are present or past employees at NovoNordisk A/S.
Acknowledgments
The authors like to thank Anders Hansen, Camilla Frost
Sorensen, and Lotte Friis for ﬁne technical in vivo
assistance and Steen Kryger, Hanife Dzaferi Farizi, Jette
Mandelbaum, and Jeanette Juul for performing ﬁne labora-
tory work for histology.
Supplementary Materials
Supplementary 1. Supplementary Table 1: materials, sera,
antibodies, and detection kits.
Supplementary 2. Supplementary Figure 1: exposure from
AdTr colitis mice using two selected doses of mouse anti-
mouse IL-21 mAb (3.3mg/kg and 25mg/kg) compared with
simulated exposure levels.
Supplementary 3. Supplementary Figure 2: transcriptional
regulation in colonic biopsies after treatment with anti-IL-
21 mAb.
Supplementary 4. Supplementary Figure 3: ablation of IL-21
signalling has no eﬀect on acute and relapsing DSS-induced
colitis. Open circles indicate IL-21R−/− mice, black squares
indicate IL-21R+/+ mice, and grey triangles indicate IL-
21R−/+ mice.
Supplementary 5. Supplementary Figure 4: ablation of IL-21
signalling has no signiﬁcant eﬀect on chronic DSS-induced
colitis. −/−mice; black squares indicate IL-21R+/+ mice. Colon
weight : length ratio (A). Endoscopic score encompassing
(thickening of the colon, changes of vascular pattern, visible
ﬁbrin, granularity of mucosal surface, stool consistency) on
day 20 (B). Histopathology score (C).
Supplementary 6. Supplementary Material and Methods.
References
[1] D. C. Baumgart and W. J. Sandborn, “Crohn’s disease,” The
Lancet, vol. 380, no. 9853, pp. 1590–1605, 2012.
[2] I. Ordás et al., “Ulcerative colitis,” The Lancet, vol. 380,
pp. 1606–1619, 2014.
[3] R. B. Sartor, “Mechanisms of disease: pathogenesis of Crohn’s
disease and ulcerative colitis,”Nature Clinical Practice. Gastro-
enterology & Hepatology, vol. 3, no. 7, pp. 390–407, 2006.
[4] J. Côté-Daigneault, M. Bouin, R. Lahaie, J. F. Colombel, and
P. Poitras, “Biologics in inﬂammatory bowel disease: what
are the data?,” United European Gastroenterology Journal,
vol. 3, no. 5, pp. 419–428, 2015.
[5] K. L. Wallace, L. B. Zheng, Y. Kanazawa, and D. Q. Shih,
“Immunopathology of inﬂammatory bowel disease,” World
Journal of Gastroenterology, vol. 20, no. 1, pp. 6–21, 2014.
[6] J. Gálvez, “Role of Th17 cells in the pathogenesis of human
IBD,” ISRN Inﬂammation, vol. 2014, Article ID 928461, 14
pages, 2014.
[7] G. Monteleone, F. Pallone, and T. T. MacDonald, “Emerging
immunological targets in inﬂammatory bowel disease,” Current
Opinion in Pharmacology, vol. 11, no. 6, pp. 640–645, 2011.
[8] T. Korn, E. Bettelli, W. Gao et al., “IL-21 initiates an alternative
pathway to induce proinﬂammatory TH17 cells,” Nature,
vol. 448, no. 7152, pp. 484–487, 2007.
20 Gastroenterology Research and Practice
[9] A. Suto, D. Kashiwakuma, S. I. Kagami et al., “Development
and characterization of IL-21–producing CD4+ T cells,” The
Journal of Experimental Medicine, vol. 205, no. 6, pp. 1369–
1379, 2008.
[10] K. Lüthje, A. Kallies, Y. Shimohakamada et al., “The devel-
opment and fate of follicular helper T cells deﬁned by an
IL-21 reporter mouse,” Nature Immunology, vol. 13, no. 5,
pp. 491–498, 2012.
[11] R. Spolski and W. J. Leonard, “Interleukin-21: a double-edged
sword with therapeutic potential,” Nature Reviews. Drug
Discovery, vol. 13, no. 5, pp. 379–395, 2014.
[12] J. M. Coquet, K. Kyparissoudis, D. G. Pellicci et al., “IL-21
is produced by NKT cells and modulates NKT cell activa-
tion and cytokine production,” The Journal of Immunology,
vol. 178, no. 5, pp. 2827–2834, 2007.
[13] S. G. Tangye, “Advances in IL-21 biology-enhancing our
understanding of human disease,” Current Opinion in Immu-
nology, vol. 34, pp. 107–115, 2015.
[14] H. Asao, C. Okuyama, S. Kumaki et al., “Cutting edge: the
common γ-chain is an indispensable subunit of the IL-21
receptor complex,” The Journal of Immunology, vol. 167,
no. 1, pp. 1–5, 2001.
[15] J. Parrish-Novak, S. R. Dillon, A. Nelson et al., “Interleukin 21
and its receptor are involved in NK cell expansion and regula-
tion of lymphocyte function,” Nature, vol. 408, no. 6808,
pp. 57–63, 2000.
[16] T. Habib, S. Senadheera, K. Weinberg, and K. Kaushansky,
“The common γ chain (γc) is a required signaling component
of the IL-21 receptor and supports IL-21-induced cell prolif-
eration via JAK3,” Biochemistry, vol. 41, no. 27, pp. 8725–
8731, 2002.
[17] W. J. Leonard and R. Spolski, “Interleukin-21: a modulator of
lymphoid proliferation, apoptosis and diﬀerentiation,” Nature
Reviews. Immunology, vol. 5, no. 9, pp. 688–698, 2005.
[18] M. Recher, L. J. Berglund, D. T. Avery et al., “IL-21 is the
primary common γ chain-binding cytokine required for
human B-cell diﬀerentiation in vivo,” Blood, vol. 118, no. 26,
pp. 6824–6835, 2011.
[19] M. C. Fantini, G. Monteleone, and T. T. MacDonald, “IL-21
comes of age as a regulator of eﬀector T cells in the gut,”Muco-
sal Immunology, vol. 1, no. 2, pp. 110–115, 2008.
[20] I. Schmitz, C. Schneider, A. Fröhlich et al., “IL-21 restricts
virus-driven Treg cell expansion in chronic LCMV infection,”
PLoS Pathogens, vol. 9, no. 5, article e1003362, 2013.
[21] B. Stockinger, M. Veldhoen, and B. Martin, “Th17 T cells: link-
ing innate and adaptive immunity,” Seminars in Immunology,
vol. 19, no. 6, pp. 353–361, 2007.
[22] G. Monteleone, I. Monteleone, D. Fina et al., “Interleukin-21
enhances T-helper cell type I signaling and interferon-γ pro-
duction in Crohn’s disease,” Gastroenterology, vol. 128, no. 3,
pp. 687–694, 2005.
[23] G. Hundorfean, M. F. Neurath, and J. Mudter, “Functional
relevance of T helper 17 (Th17) cells and the IL-17 cytokine
family in inﬂammatory bowel disease,” Inﬂammatory Bowel
Diseases, vol. 18, no. 1, pp. 180–186, 2012.
[24] E. Troncone, I. Maraﬁni, F. Pallone, and G. Monteleone,
“Th17 cytokines in inﬂammatory bowel diseases: discerning
the good from the bad,” International Reviews of Immunology,
vol. 32, no. 5-6, pp. 526–533, 2013.
[25] M. A. Kleinschek, K. Boniface, S. Sadekova et al., “Circulating
and gut-resident human Th17 cells express CD161 and
promote intestinal inﬂammation,” The Journal of Experimen-
tal Medicine, vol. 206, no. 3, pp. 525–534, 2009.
[26] Z. Hovhannisyan, J. Treatman, D. R. Littman, and L. Mayer,
“Characterization of interleukin-17–producing regulatory
T cells in inﬂamed intestinalmucosa frompatients with inﬂam-
matory bowel diseases,” Gastroenterology, vol. 140, no. 3,
pp. 957–965, 2011.
[27] M.A. van Leeuwen, D. J. Lindenbergh-Kortleve, H. C. Raatgeep
et al., “Increased production of interleukin-21, but not interleu-
kin-17A, in the small intestine characterizes pediatric celiac
disease,” Mucosal Immunology, vol. 6, no. 6, pp. 1202–1213,
2013.
[28] F. Pallone, D. Fina, R. Caruso, and G. Monteleone, “Role of IL-
21 in inﬂammatory bowel disease,” Expert Review of Clinical
Immunology, vol. 6, no. 4, pp. 537–541, 2014.
[29] Z. Wang, L. Ding, Z. Wang et al., “Circulating CD4+CXCR5+
T cells exacerbate B cell antibody production in Crohn’s dis-
ease through IL-21 secretion,” Immunological Investigations,
vol. 44, no. 7, pp. 665–677, 2015.
[30] D. Herber, T. P. Brown, S. Liang, D. A. Young, M. Collins, and
K. Dunussi-Joannopoulos, “IL-21 has a pathogenic role in a
lupus-prone mouse model and Its blockade with IL-21R.Fc
reduces disease progression,” The Journal of Immunology,
vol. 178, no. 6, pp. 3822–3830, 2007.
[31] D. Fina, M. Sarra, M. C. Fantini et al., “Regulation of gut
inﬂammation and Th17 cell response by Interleukin-21,” Gas-
troenterology, vol. 134, no. 4, pp. 1038–1048.e2, 2008.
[32] J. A. Bubier, S. M. Bennett, T. J. Sproule et al., “Treatment of
BXSB-Yaa mice with IL-21R-Fc fusion protein minimally
attenuates systemic lupus erythematosus,” Annals of the New
York Academy of Sciences, vol. 1110, no. 1, pp. 590–601, 2007.
[33] D. A. Young, M. Hegen, H. L. M. Ma et al., “Blockade of the
interleukin-21/interleukin-21 receptor pathway ameliorates
disease in animal models of rheumatoid arthritis,” Arthritis
and Rheumatism, vol. 56, no. 4, pp. 1152–1163, 2007.
[34] M. . C. Fantini, A. Rizzo, D. Fina et al., “IL-21 regulates exper-
imental colitis by modulating the balance between Treg and
Th17 cells,” European Journal of Immunology, vol. 37, no. 11,
pp. 3155–3163, 2007.
[35] R. Caruso, D. Fina, I. Peluso et al., “A functional role for
interleukin-21 in promoting the synthesis of the T-cell che-
moattractant, MIP-3α, by gut epithelial cells,” Gastroenterol-
ogy, vol. 132, no. 1, pp. 166–175, 2007.
[36] G. Monteleone, R. Caruso, D. Fina et al., “Control of matrix
metalloproteinase production in human intestinal ﬁbroblasts
by interleukin 21,” Gut, vol. 55, no. 12, pp. 1774–1780, 2006.
[37] B. Erman, I. Bilic, T. Hirschmugl et al., “Combined immuno-
deﬁciency with CD4 lymphopenia and sclerosing cholangitis
caused by a novel loss-of-function mutation aﬀecting IL21R,”
Haematologica, vol. 100, no. 6, pp. e216–e219, 2015.
[38] E. Salzer, A. Kansu, H. Sic et al., “Early-onset inﬂammatory
bowel disease and common variable immunodeﬁciency–like
disease caused by IL-21 deﬁciency,” Journal of Allergy and
Clinical Immunology, vol. 133, no. 6, pp. 1651–1659.e12, 2014.
[39] P. Stepensky, B. Keller, O. Abuzaitoun et al., “Extending the
clinical and immunological phenotype of human interleukin-
21 receptor deﬁciency,” Haematologica, vol. 100, no. 2,
pp. e72–e76, 2015.
[40] M. Croce, V. Rigo, and S. Ferrini, “IL-21: a pleiotropic cytokine
with potential applications in oncology,” Journal of Immunol-
ogy Research, vol. 2015, Article ID 696578, 15 pages, 2015.
21Gastroenterology Research and Practice
[41] C. Liu, X. Xia, W.Wu et al., “Anti-tumour necrosis factor ther-
apy enhances mucosal healing through down-regulation of
interleukin-21 expression and T helper type 17 cell inﬁltration
in Crohn’s disease,” Clinical & Experimental Immunology,
vol. 173, no. 1, pp. 102–111, 2013.
[42] L. Yu, X. Yang, L. Xia et al., “Inﬂiximab preferentially induces
clinical remission and mucosal healing in short course Crohn’s
disease with luminal lesions through balancing abnormal
immune response in gut mucosa,”Mediators of Inﬂammation,
vol. 2015, 9 pages, 2015.
[43] P. Kristensen, J. Eriksen, and K. Danø, “Localization of
urokinase-type plasminogen activator messenger RNA in
the normal mouse by in situ hybridization,” Journal of
Histochemistry & Cytochemistry, vol. 39, no. 3, pp. 341–
349, 2017.
[44] M. G. Willesen, P. Kristensen, and J. Rømer, “Co-localization
of growth hormone Secretagogue receptor and NPY mRNA
in the arcuate nucleus of the rat,” Neuroendocrinology,
vol. 70, no. 5, pp. 306–316, 1999.
[45] T. Nevalainen, H. J. M. Blom, A. Guaitani, P. Hardy, B. R.
Howard, and P. Vergara, “FELASA recommendations for the
accreditation of laboratory animal science education and
training: report of the Federation of European Laboratory Ani-
mal Science Associations Working Group on accreditation of
laboratory animal science education and training,” Laboratory
Animals, vol. 36, no. 4, pp. 373–377, 2016.
[46] T. Lindebo Holm et al., “Pharmacological evaluation of the
SCID T cell transfer model of colitis: as a model of Crohn’s dis-
ease,” International Journal of Inﬂammation, vol. 2012, Article
ID 412178, 11 pages, 2012.
[47] S. Kjellev, D. Lundsgaard, S. S. Poulsen, and H. Markholst,
“Reconstitution of Scid mice with CD4+CD25− T cells leads
to rapid colitis: an improved model for pharmacologic
testing,” International Immunopharmacology, vol. 6, no. 8,
pp. 1341–1354, 2006.
[48] K. Holgersen, P. H. Kvist, A. K. Hansen, and T. L. Holm, “Pre-
dictive validity and immune cell involvement in the pathogen-
esis of piroxicam-accelerated colitis in interleukin-10
knockout mice,” International Immunopharmacology, vol. 21,
no. 1, pp. 137–147, 2014.
[49] K. Holgersen, P. H. Kvist, H. Markholst, A. K. Hansen, and
T. L. Holm, “Characterisation of enterocolitis in the
piroxicam-accelerated interleukin-10 knock out mouse — a
model mimicking inﬂammatory bowel disease,” Journal of
Crohn's and Colitis, vol. 8, no. 2, pp. 147–160, 2014.
[50] M. Coskun, A. K. Olsen, T. L. Holm et al., “TNF-α-induced
down-regulation of CDX2 suppresses MEP1A expression in
colitis,” Biochimica et Biophysica Acta (BBA) - Molecular Basis
of Disease, vol. 1822, no. 6, pp. 843–851, 2012.
[51] J. B. Seidelin, M. Coskun, P. H. Kvist, T. L. Holm,
K. Holgersen, and O. H. Nielsen, “IL-33 promotes GATA-3
polarization of gut-derived T cells in experimental and
ulcerative colitis,” Journal of Gastroenterology, vol. 50, no. 2,
pp. 180–190, 2015.
[52] C. Becker, M. C. Fantini, and M. F. Neurath, “High resolution
colonoscopy in live mice,” Nature Protocols, vol. 1, no. 6,
pp. 2900–2904, 2007.
[53] K. Holgersen, B. Kutlu, B. Fox et al., “High-resolution gene
expression proﬁling using RNA sequencing in patients with
inﬂammatory bowel disease and in mouse models of colitis,”
Journal of Crohn's and Colitis, vol. 9, no. 6, pp. 492–506, 2015.
[54] P. Brandtzaeg, H. Kiyono, R. Pabst, and M. W. Russell,
“Terminology: nomenclature of mucosa-associated lymphoid
tissue,” Mucosal Immunology, vol. 1, no. 1, pp. 31–37, 2008.
[55] M. Sarra, I. Monteleone, C. Stolﬁ et al., “Interferon-gamma-
expressing cells are a major source of interleukin-21 in inﬂam-
matory bowel diseases,” Inﬂammatory Bowel Diseases, vol. 16,
no. 8, pp. 1332–1339, 2010.
[56] Z. Liu, L. Yang, Y. Cui et al., “Il-21 enhances NK cell activation
and cytolytic activity and induces Th17 cell diﬀerentiation in
inﬂammatory bowel disease,” Inﬂammatory Bowel Diseases,
vol. 15, no. 8, pp. 1133–1144, 2009.
[57] W. Jiang, J. Su, X. Zhang et al., “Elevated levels of Th17 cells
and Th17-related cytokines are associated with disease activity
in patients with inﬂammatory bowel disease,” Inﬂammation
Research, vol. 63, no. 11, pp. 943–950, 2014.
[58] C. Stolﬁ, A. Rizzo, E. Franzè et al., “Involvement of interleukin-
21 in the regulation of colitis-associated colon cancer,” The
Journal of Experimental Medicine, vol. 208, no. 11, pp. 2279–
2290, 2011.
[59] J. Yu, S. He, P. Liu et al., “Interleukin-21 promotes the develop-
ment of ulcerative colitis and regulates the proliferation and
secretion of follicular T helper cells in the colitides microenvi-
ronment,” Molecular Medicine Reports, vol. 11, no. 2,
pp. 1049–1056, 2015.
[60] C. Poholek and L. Harrington, “The role of interleukin-21 in
the pathogenesis of inﬂammatory bowel disease,” The Journal
of Immunology, vol. 188, Supplement 1, p. 123.45, 2012.
[61] C. Poholek and L. Harrington, “Interleukin-21 drives intesti-
nal inﬂammation by bridging the adaptive and innate immune
compartments,” The Journal of Immunology, vol. 190, Supple-
ment 1, p. 171.3, 2013.
[62] A. Yeste, I. D. Mascanfroni, M. Nadeau et al., “IL-21 induces
IL-22 production in CD4+ T cells,” Nature Communications,
vol. 5, 2014.
[63] I. Peluso, M. C. Fantini, D. Fina et al., “IL-21 counteracts the
regulatory T cell-mediated suppression of human CD4+ T
lymphocytes,” The Journal of Immunology, vol. 178, no. 2,
pp. 732–739, 2007.
[64] Y. Wang, X. Jiang, J. Zhu et al., “IL-21/IL-21R signaling sup-
presses intestinal inﬂammation induced by DSS through regu-
lation of Th responses in lamina propria in mice,” Scientiﬁc
Reports, vol. 6, no. 1, p. 31881, 2016.
22 Gastroenterology Research and Practice
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
